Brokerages expect Cellectis S.A. (NASDAQ:CLLS) to post sales of $10.56 million for the current fiscal quarter, Zacks Investment Research reports. Two analysts have made estimates for Cellectis’ earnings. The lowest sales estimate is $10.00 million and the highest is $11.12 million. Cellectis posted sales of $12.62 million in the same quarter last year, which suggests a negative year over year growth rate of 16.3%. The firm is expected to issue its next quarterly earnings results on Tuesday, November 28th.

On average, analysts expect that Cellectis will report full year sales of $10.56 million for the current fiscal year, with estimates ranging from $39.70 million to $44.00 million. For the next year, analysts anticipate that the company will report sales of $40.15 million per share, with estimates ranging from $36.00 million to $44.46 million. Zacks’ sales averages are a mean average based on a survey of research analysts that follow Cellectis.

Several brokerages have recently commented on CLLS. BidaskClub raised Cellectis from a “strong sell” rating to a “sell” rating in a report on Wednesday, August 23rd. Jefferies Group LLC set a $47.00 price objective on Cellectis and gave the company a “buy” rating in a research report on Friday, August 25th. Zacks Investment Research raised Cellectis from a “hold” rating to a “buy” rating and set a $32.00 price objective on the stock in a research note on Wednesday, July 19th. Wells Fargo & Company reissued an “outperform” rating and issued a $40.00 price objective (up previously from $33.00) on shares of Cellectis in a research note on Tuesday, September 5th. Finally, Nomura decreased their target price on Cellectis from $49.00 to $43.00 and set a “buy” rating on the stock in a report on Wednesday, September 6th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and six have issued a buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $39.00.

ILLEGAL ACTIVITY WARNING: “Cellectis S.A. (CLLS) Expected to Post Quarterly Sales of $10.56 Million” was first posted by American Banking News and is the property of of American Banking News. If you are accessing this piece of content on another domain, it was illegally copied and republished in violation of United States and international trademark and copyright law. The correct version of this piece of content can be read at

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Sphera Funds Management LTD. grew its position in shares of Cellectis by 27.6% during the 2nd quarter. Sphera Funds Management LTD. now owns 203,764 shares of the biotechnology company’s stock worth $5,261,000 after buying an additional 44,100 shares during the period. Balyasny Asset Management LLC bought a new position in Cellectis during the 2nd quarter worth approximately $719,000. Williams Jones & Associates LLC acquired a new position in Cellectis during the second quarter valued at approximately $244,000. Trexquant Investment LP acquired a new position in Cellectis during the first quarter valued at approximately $214,000. Finally, Wells Fargo & Company MN grew its holdings in Cellectis by 132.1% during the second quarter. Wells Fargo & Company MN now owns 9,550 shares of the biotechnology company’s stock valued at $247,000 after purchasing an additional 5,435 shares during the period. Institutional investors and hedge funds own 14.85% of the company’s stock.

Shares of Cellectis (NASDAQ:CLLS) traded up 1.8034% during mid-day trading on Wednesday, hitting $29.1565. The company had a trading volume of 54,899 shares. Cellectis has a 12-month low of $16.09 and a 12-month high of $30.46. The firm’s 50 day moving average is $27.87 and its 200-day moving average is $27.87. The firm’s market cap is $1.05 billion.

Cellectis Company Profile

Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development and commercialization of rational genome engineering technologies. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement.

Get a free copy of the Zacks research report on Cellectis (CLLS)

For more information about research offerings from Zacks Investment Research, visit

Earnings History and Estimates for Cellectis (NASDAQ:CLLS)

Receive News & Ratings for Cellectis S.A. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis S.A. and related companies with's FREE daily email newsletter.